Accord Healthcare Limited announces that the European Commission (EC) has granted marketing authorisation for Imuldosa (development code: DMB-3115), a biosimilar of Stelara (ustekinumab), marketed by The Janssen Pharmaceutical Companies of Johnson & Johnson Read more: https://lnkd.in/eEwrqmw7 #pharmanews #pharmaceuticalindustry #biosimilars #biopharma #ustekinumab #accordhealthcare #janssenbiotech #worldpharma
